The growing use of weight-loss medications among younger women has created an unexpected reproductive health scenario: drugs designed to treat obesity may be inadvertently restoring fertility while raising questions about pregnancy safety. This development particularly affects women with polycystic ovary syndrome and obesity-related fertility challenges who may suddenly find themselves able to conceive.
This comprehensive review of studies from 2020-2025 reveals that GLP-1 receptor agonists like semaglutide and liraglutide appear to improve ovulatory function and menstrual regularity in women with metabolic disorders. The mechanism likely involves weight loss-induced hormonal rebalancing and direct effects on reproductive tissues. However, human pregnancy exposure data remains sparse, with most safety evidence derived from small cohorts and inconsistent study methodologies.
The fertility restoration effect creates a clinical paradox: while these medications may help women with obesity-related infertility conceive, the safety profile during pregnancy remains incompletely characterized. Current evidence suggests no strong teratogenic signals, but this conclusion rests on limited data. The situation is further complicated by unintended pregnancies occurring when fertility unexpectedly returns during treatment.
This represents a significant knowledge gap in reproductive medicine. Unlike traditional fertility treatments with established pregnancy protocols, GLP-1 medications entered widespread use without comprehensive reproductive safety studies. For the growing population of reproductive-age women using these drugs, the intersection of metabolic treatment and fertility outcomes demands urgent research attention and clear clinical guidelines.